• Majority stockholders delivered a written consent removing directors Elona Kogan, Jakap Koo, Carol O'Donnell and Dr. Bennett Weintraub, effective immediately.
• The same action appointed Youngjik Cho, Minguk Ji and Junyoung Yu as directors, effective immediately, with Minguk Ji and Junyoung Yu identified as independent.
• Following the board changes, the board removed Vin Menon as chief executive officer and appointed Youngjik Cho as chief executive officer and chairman, effective immediately.
• The board also removed Erick Frim as chief financial officer and appointed Junyoung Yu as secretary, effective immediately.
• Minguk Ji and Junyoung Yu joined the audit, compensation, and nominating and corporate governance committees, with Junyoung Yu chairing the audit and nominating and corporate governance committees and Minguk Ji chairing the compensation committee.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-033832), on March 25, 2026, and is solely responsible for the information contained therein.